Human Papillomavirus (HPV) News and Research

Latest Human Papillomavirus (HPV) News and Research

Survey finds women interested in human papillomavirus vaccination

Cost but not convenience plays a significant role in attitudes about vaccination for common human papillomaviruses for women over the age of 26, according to the authors of a recent article in the journal Sexual Health.

25 Aug 2010

Fewer young women going for regular pap smears

According to new research findings, the number of young women going for a regular Pap smear test is dwindling. This test is a simple procedure that looks at the cervical cells and can detect cervical cancer early on. In 2001-02, 67% Australian women aged 20-69 went for a Pap smear, a number that went down to 60% in 2008-09. These are the lowest rates in the decade.

24 Aug 2010

Immunization rate increases among teens: NIS report

In light of today's report of the National Immunization Survey results, the Society for Adolescent Health and Medicine (SAHM) encourages increased efforts in fully immunizing all adolescents.

21 Aug 2010

Scientists suggest immunization against oncogenic herpesviruses can prevent cancer

Viruses that can invade host cells, initiate cancer and then flee fromb their own trail of destruction could be stopped in their tracks, say researchers writing in the September issue of the Journal of General Virology.

19 Aug 2010

Pharmacists in all states authorized to administer influenza vaccines

The American Pharmacists Association (APhA) is encouraging consumers to get immunized against influenza and to consider their local pharmacy as the site to receive their vaccine. Pharmacists in all 50 states including the District of Columbia are authorized to administer influenza vaccines and, as of June 30, 2010, more than 120,000 U.S. pharmacists have been trained to administer immunizations.

18 Aug 2010

Inovio Pharmaceuticals 2010 second quarter net loss decreases

Inovio Pharmaceuticals, Inc. today reported financial results for the quarter ended June 30, 2010.Total revenue was $1.1 million and $2.5 million for the three and six months ended June 30, 2010, compared to $2.5 million and $2.9 million for the three and six months ended June 30, 2009, respectively.

16 Aug 2010

Patient navigator program to educate Hmong women on cervical cancer

The Asian-American community of Hmong women in California carries a stunning burden of cervical cancer and resulting mortality four times as high as non-Hispanic white women in California do.

7 Aug 2010

Summer Academy Meeting highlights benefits of HPV, Herpes Zoster vaccines

Vaccines have a long history of successfully preventing disease and, in effect, improving the lives of countless Americans. Now, two serious diseases - human papillomavirus (HPV) and herpes zoster - could become a thing of the past as people better understand the safety and efficacy of vaccines to prevent these serious viral infections in specific populations.

6 Aug 2010

Scientists develop laser probe for early detection of oral cancer

UC Davis researchers have developed a laser probe for the early detection of oral cancer. A trial with human subjects shows that the device could also be used during surgery to locate the edges of a tumor.

5 Aug 2010

Premier international conference to discuss latest diagnostic tools, emerging therapies for personalized medicine

What As scientists understand more about a tumor's underlying biology, personalized medicine is emerging as the new patient management paradigm. This year, the American Association for Cancer Research will host its fourth Molecular Diagnostics in Cancer Therapeutic Development: Challenges and Horizons conference at the Sheraton Denver Downtown Hotel in Denver, Colo. This meeting regularly draws representatives from academia and industry to discuss the latest in diagnostic tools and emerging therapies.

4 Aug 2010

Survey on administrating human papillomavirus vaccine for cervical cancer prevention

The vast majority of pediatricians and family physicians nationally are offering the human papillomavirus (also called HPV) vaccine, though fewer physicians are strongly encouraging it for 11- to 12-year-old girls as recommended by national guidelines, according to a survey in the September issue of Pediatrics, the journal of the American Academy of Pediatrics.

3 Aug 2010

Merck reports strong bottom-line performance in second quarter

Merck & Co., Inc. today announced financial results for the second quarter of 2010. The company reported non-GAAP (generally accepted accounting principles) earnings per share (EPS) for the second quarter of $0.86, which excludes purchase accounting adjustments, merger-related expenses, restructuring costs and the gain on AstraZeneca's asset option exercise. Second-quarter GAAP EPS was $0.24.

2 Aug 2010

DIATHERIX Laboratories opens rapid response diagnostic panels for STD, HSV

DIATHERIX Laboratories ,adds a Sexually Transmitted Disease (STD) panel and Herpes Simplex Virus (HSV) panel to its line up of highly sensitive, rapid response diagnostic panels. The HSV panel identifies herpes simplex viruses 1 and 2 and the STD panel identifies 10 sexually transmitted diseases simultaneously, many of which cannot be accurately identified by current testing methods. These STD organisms, if not appropriately treated, can cause diseases such as syphilis, gonorrhoeae, chlamydia, bacterial vaginosis, etc. and may lead to blindness, infertility or complications during pregnancy.

28 Jul 2010

Einstein scientists awarded $4.1M to test microbicide Carraguard against HPV

The National Cancer Institute has awarded Albert Einstein College of Medicine of Yeshiva University $4.1 million to test the microbicide Carraguard- against the human papillomavirus, which causes cervical cancer. The research will evaluate the efficacy of Carraguard- - a clear gel made from the seaweed derivative carrageenan - in preventing new HPV infections in women.

26 Jul 2010

Cervical cancer vaccine could reduce number of cases from 3,000 to less than 700 every year

The cervical cancer vaccine could prevent even more cases of the disease in England than previously thought, UK scientists have found.

15 Jul 2010

Starpharma gets FDA nod to start phase 2 bacterial vaginosis study for VivaGel

Starpharma Holdings Limited (ASX:SPL, OTCQX:SPHRY) today announced it had received clearance from the US Food and Drug Administration (FDA) to commence a phase 2 study to investigate VivaGel® for the treatment of bacterial vaginosis (BV).

15 Jul 2010

QIAGEN's digene HPV Test improves cervical cancer control: Study

A study released today "online first" in Cancer Causes & Control demonstrates that human papillomavirus testing, using QIAGEN's digene HPV Test, improved cervical cancer control compared to routine Pap (cytology) testing among 50,000 women across Mexico, the first country in Latin America to implement a national screening program for the high-risk types of HPV that can cause cervical cancer.

From QIAGEN Manchester Limited 13 Jul 2010

Phase III study results of imiquimod creams for treatment of EGW presented at HPV Conference

Results from a Phase III program evaluating imiquimod 3.75% and 2.5% creams for the treatment of EGW, applied once daily for up to 8 weeks, demonstrated that both were well-tolerated and more efficacious than placebo, according to data presented at the annual Human Papillomavirus Conference in Montreal, July 3 - 8. Investigators found that efficacy was greatest for imiquimod 3.75% with an enhanced safety profile.

9 Jul 2010

Screening for HPV genotypes 16 and 18 helps detect cervical pre-cancer missed by Pap test

Roche today announced that data from the ATHENA (Addressing THE Need for Advanced HPV Diagnostics) U.S. registration trial of over 47,000 women demonstrate that two human papillomavirus genotypes, HPV 16 and HPV 18, can identify those women with cervical pre-cancer missed by cytologic examination with a Papanicolau (Pap) test.

From Roche Sequencing and Life Science 9 Jul 2010

Clinical performance data of Cervista HPV HR presented at International Papillomavirus Conference

Hologic, Inc., a leading women's healthcare company, today announced that final data analysis from the first large-scale independent evaluation of clinical performance of Cervista HPV HR compared to Hybrid Capture 2, were presented in Montreal, Canada, at the 26th International Papillomavirus Conference. Cervista HPV HR is a diagnostic test for the detection of 14 high-risk human papillomavirus types.

8 Jul 2010

Human Papillomavirus (HPV) News and Research

Latest Human Papillomavirus (HPV) News and Research

Survey finds women interested in human papillomavirus vaccination

Fewer young women going for regular pap smears

Immunization rate increases among teens: NIS report

Scientists suggest immunization against oncogenic herpesviruses can prevent cancer

Pharmacists in all states authorized to administer influenza vaccines

Inovio Pharmaceuticals 2010 second quarter net loss decreases

Patient navigator program to educate Hmong women on cervical cancer

Summer Academy Meeting highlights benefits of HPV, Herpes Zoster vaccines

Scientists develop laser probe for early detection of oral cancer

Premier international conference to discuss latest diagnostic tools, emerging therapies for personalized medicine

Survey on administrating human papillomavirus vaccine for cervical cancer prevention

Merck reports strong bottom-line performance in second quarter

DIATHERIX Laboratories opens rapid response diagnostic panels for STD, HSV

Einstein scientists awarded $4.1M to test microbicide Carraguard against HPV

Cervical cancer vaccine could reduce number of cases from 3,000 to less than 700 every year

Starpharma gets FDA nod to start phase 2 bacterial vaginosis study for VivaGel

QIAGEN's digene HPV Test improves cervical cancer control: Study

Phase III study results of imiquimod creams for treatment of EGW presented at HPV Conference

Screening for HPV genotypes 16 and 18 helps detect cervical pre-cancer missed by Pap test

Clinical performance data of Cervista HPV HR presented at International Papillomavirus Conference

Advancing brain microphysiological systems (bMPS)

PhD researcher at LifeArc

Unveiling Hidden Potential: Organoids for Disease Modeling in Neuroscience Research

Human Papillomavirus (HPV) News and Research

Latest Human Papillomavirus (HPV) News and Research

Advancing brain microphysiological systems (bMPS)

PhD researcher at LifeArc

Unveiling Hidden Potential: Organoids for Disease Modeling in Neuroscience Research

Newsletters you may be interested in